Countdown to 2019 CBIIC:

Brief Introduction of CBIIC

China BioMed Innovation and Investment Conference (CBIIC) was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. As an annual grand conference to promote the communication between pharmaceutical industry and investment industry, CBIIC aims to integrate the power of pharmaceutical innovation and investment at home and abroad to build an authorized, comprehensive, professional and international high level platform where the industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises and investors can learn the trend of innovation, seek high value projects and discuss new investment channels and innovative cooperation strategies to facilitate the timely transformation of unmet clinical needs and promote the pharmaceutical innovation serve the public health.

Established by PhIRDA, CBIIC has successively co-hosted by Securities Association of China (SAC), China Association for Medical Devices Industry (CAMDI), Hong Kong Exchanges and Clearing Limited (HKEX) and Chinese Hospital Association (CHA) and other organizations from 2016 to 2018. Under the principle of ‘promoting the linkage between social capital and pharmaceutical innovation, and improving the innovation capability of pharmaceutical industry’, focusing on the current trend of pharmaceutical innovation and investment, CBIIC invited government officials, global important guests from pharmaceutical and investment communities, and set domestic and foreign innovative projects roadshows, and various forums involving investment and pharmaceutical policies. By the end of 2018, over 6,500 participants attended CBIIC, 25 new drugs had made their global first clinical trial data release, more than 300 innovative projects at home and abroad had presented in the roadshows, including representatives from 1,500 pharmaceutical enterprises and 1,000 investment institutions. CBIIC has become a well-established event highly welcomed and praised by pharmaceutical and investment industry.

2019 CBIIC will hold in Suzhou from September 21-23, with over 3500 expected participants.
The highlights of the 2019 CBIIC:

I. Innovational Roadshows and Parallel Sessions to Meet Diverse Needs

To open financing channel for pharmaceutical innovation, serve the innovative pharmaceutical entities with capital, adhere to value-oriented principle, CBIIC always includes activities around latest and hottest issues of pharmaceutical innovation; almost 20 special roadshows and parallel sessions including the newly set WIT-MED + Big Data, Artificial Intelligence (AI) + BioMed, Service Company (CRO, CMO, CDMO), Science and Technology Innovation Board, along with the Opening Ceremony, Clinical Trial Data Release, Rare Diseases and Orphan Drugs, Medical Devices, and Investors’ Experience Sharing, Cross Border M&A, etc. will present an excellent event to meet diversified needs of participants.

II. Hot Discussion on the Development and Future of Global Innovation Financing Platform by KOLs from Top Leading 4 Stock Exchanges

2019 CBIIC invites KOLs from 4 leading stock exchanges, including HKEX, NASDAQ, London Stock Exchange, and Shanghai Stock Exchange. Charles LI, Chief Executive of HKEX, Wilfred Yiu, Head of Markets of HKEX, and senior representatives from NASDAQ, London Stock Exchange and Shanghai Stock Exchange will attend the event to discuss the development and future of global innovation financing platform, to assist domestic enterprises to find the cross-border financing channel, and to promote China’s capability on pharmaceutical innovation transformation. Mr. Charles LI will deliver a keynote speech.

III. Inspiring Speech for R&D and Investment Made by Global Leading Immunologist & Chinese Scientist

Dr. LIU Yongjun, world-renowned scientist in immunobiology and global head of research of Sanofi, will attend the Opening Ceremony and give a keynote speech, introducing the latest global development of tumor immunotherapy, and picturing the future trend of immunotherapy.

IV. One-on-One Partnering System for Close Business Communication between CBIIC Participants

To facilitate effective communication and precise cooperation between domestic and foreign pharmaceutical innovators and investors, 2019 CBIIC will build a better and more diverse platform for project presentation and communication. In addition to the company booths, 2019 CBIIC will provide a One-on-One partnering service for participants to seek potential business partners easily and efficiently.

We believe that under the great support of all parties, CBIIC is becoming a extensive influential, authoritative, diversified event for showing pharmaceutical innovative achievements and investment trends in China and around the world, as well as a communicative platform for international cooperation. To build a grand event in Asia-Pacific region, CBIIC is making social capital playing an irreplaceable key role in the development of pharmaceutical innovation, creating a more scientific and attractive investment environment and contributing to China's economic and social development to meet the clinical needs and advance the pursuit of Healthy China.

————

700+

Pharmaceutical Companies

————

500+

Investment Institutions

————

3500+

Participants